{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-107898","form_type":"8-K","ticker":"COCH","cik":"0001840877","company_name":"Envoy Medical, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.751421+00:00","generated_at":"2026-05-16T22:35:51.893879+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Envoy Medical eliminates $32M debt, gets FDA approval to expand cochlear implant trial","bullets":["Extinguished over $32 million in debt, strengthening balance sheet without equity issuance.","Post-quarter: FDA approved expansion of pivotal clinical trial to final stage; three patients enrolled.","Closed up to $16 million registered direct offering priced at-the-market under Nasdaq rules.","Q3 net revenue $42,000; R&D expenses $2.7M; cash $3.556M as of Sept. 30, 2025.","Expanded global patent portfolio with four new patents in U.S., Europe, and Australia."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-107898","json":"https://secwatch.observer/filing/0001213900-25-107898.json","markdown":"https://secwatch.observer/filing/0001213900-25-107898.md","text":"https://secwatch.observer/filing/0001213900-25-107898.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840877/000121390025107898/0001213900-25-107898-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840877/000121390025107898/ea0264709-8k_envoy.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:35:51.893879+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}